Galectin Therapeutics Inc., of Norcross, Ga., said it completed enrollment in its phase II trial of GR-MD-02, a complex carbohydrate targeting galectin-3, in patients with non-alcoholic steatohepatitis with advanced fibrosis. The NASH-FX trial enrolled a total of 30 liver biopsy-confirmed patients and is assessing fibrosis using multiparametric magnetic resonance imaging as the primary endpoint. Top-line results are expected by the end of September.